Navigation Links
Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech
Date:3/26/2009

Epinex Test Could Transform Diabetes Care

IRVINE, Calif., March 26 /PRNewswire/ -- On March 18th, Frost & Sullivan presented Epinex with its prestigious global diabetes research award. The award was given in recognition of Epinex's innovative G1A(TM) Rapid Diabetes Monitoring Index Test, which uses glycated albumin to measure the damage caused by excess sugar in the body.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090326/LA89768)

Diabetes is one of the biggest contributors to our healthcare crisis. Preventive care programs could significantly reduce the human and financial costs of diabetes. The impending shift to preventive care has opened the door for a small company like Epinex to make a big difference in the healthcare system and in the lives of diabetics. The Epinex G1A(TM) test has the potential to transform diabetes care by introducing a more effective monthly diabetes management paradigm.

Preventive care will drive healthcare policy in the future. In his effort to revamp our crippled healthcare system, President Obama has called for investing unprecedented resources into preventive health care. President Obama once again targeted healthcare reform as the best way to "bend the curve on...deficit projections" at his news conference on Tuesday.

"The current economic crisis has leveled the playing field between Main Street and Wall Street," declared Epinex CEO Asad Zaidi during his acceptance speech. "As a Main Street biotech company, this award validates our work and will motivate us to...bring paradigm shifting disruptive technology into the marketplace. This award gives us the energy and momentum to break through the resistance of established medical practices."

The Obama Administration has called for "tough choices" in cutting medical costs. Healthcare companies are challenged to respond by investing in innovative products that will meet future healthcare needs. Epinex's award-winning research has been recognized as a step forward in meeting that challenge.

About Epinex Diagnostics, Inc.

Epinex Diagnostics is a privately owned medical device company with a vision to help alleviate the current healthcare crisis through the development of innovative point-of-care technologies using rapid diagnostic tests. Please find further information about the company and the G1A(TM) test at www.epinex.com.

    Contact:
    Jacqueline Morales
    Public Relations
    Epinex Diagnostics, Inc.
    Phone 949-660-7770, ext. 106
    jacqueline@epinex.com


'/>"/>
SOURCE Epinex Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
2. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
3. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
4. Frost & Sullivan: In Vitro Diagnostics Market
5. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
6. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
7. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
8. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
9. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
10. Frost & Sullivan to Present the 2009 Excellence in Medical Technologies & Life Sciences Awards
11. Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):